• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.
By DEBRA BORCHARDT
Aug 01, 2018 | 11:06 AM EDT
Stocks quotes in this article: INSY, GWPH, CRPB, ZYNE

Insys Therapeutics  (INSY) likes to pretend it's a cannabis stock -- but it really isn't. Instead, this biotech company has tried to ride the coattails of biotech company GW Pharmaceuticals  (GWPH) and its cannabinoid-based epileptics drug Epidiolex. Insys continues to suck in investors who think the company is ripe for a good study result or positive nod from the U.S. Food & Drug Administration (FDA) -- and that its cheap.

The latest rejection came on Friday when the FDA decided not to approve Insys' drug buprenorphine sublingual spray to treat pain as an alternative to opioids. The stock got slapped down almost 9% at one point as a result.

"Given the attributes of our proprietary buprenorphine formulation for sublingual delivery, we continue to believe that this drug-device combination could bring value to the management of pain and will assess the next steps in the context of the company's overall mission," said Steve Sherman, senior vice president of regulatory affairs for Insys Therapeutics.

The company said that the FDA's Complete Response Letter "indicates that, although the clinical development program demonstrated all three proposed doses of the product candidate were statistically significantly different than placebo in providing pain relief, some of the data suggested potential safety concerns." In other words, the FDA ruled that it isn't safe to take this drug in its present form.

At the beginning of May, in its first quarter earnings announcement, Insys said it provided additional safety data to the FDA on this drug. So, the company knew it had issues with the drug but continued to push it forward. Then two weeks later, Insys said that the expert panel convened by the FDA had voted not to recommend the drug and the stock was trading around $7.07. Still, it moved higher as news came out that GW Pharmaceutical's Epidiolex got FDA approval. It went to $8.41 at the end of June and then jumped back up to $8.29 in mid-July.

Some traders also jumped back into the stock after a judge questioned the racketeering charges against the Insys founder John Kapoor. He's accused of bribing doctors to prescribe its opioid pain killer Subsys -- the source of most of the company's revenue. That news seemed to suggest to some investors that maybe the negative headlines and scandal could be diminishing. The company is desperate to move past the alleged kickback scheme charges and focus on CBD as its future.

Insys has two cannabinoid (CBD) drugs. One is a CBD oral solution called Syndros and the other is a Donabinol inhalation product. Syndros is on the market and is considered to be a liquid form of Marinol, the synthetic cannabis drug. The problem here is that patients don't like Marinol and often quit taking it, so a liquid version isn't going to be much more successful than the pill option. Dronabinol is a synthetic form of THC, the psychoactive part of the cannabis plant, and is mostly used for patients that need help eating.

Also, patients can now get real medical marijuana in over half of the states in the U.S., and many say that they prefer the real plant over a synthetic version with numerous side effects. Marinol was once a big deal because it was considered legal marijuana, but since so many states have legalized medical marijuana, the lure of Marinol has worn off. 

Indeed, one of the big positives for GW Pharma's drug is that it is real, not synthetic cannabis. Yet, it never fails that when analysts talk about GW Pharma's positive moves, they typically lump Insys in along with it. Moody's wrote in May, "A Food and Drug Administration (FDA) advisory panel recently recommended that the FDA approve the drug (Epidiolex) in those uses. Other development-stage companies working on CBD-based pharmaceutical products include INSYS Therapeutics, Corbus Pharmaceuticals (CRPB)  and Zynerba Pharmaceuticals (ZYNE)  -- all unrated." (Corbus is another fake cannabis drug company -- but that's a column for another day.)

JP Morgan Chase has increased its stake in Insys from 19,273 shares to 25,624 shares. Other firms have done the same, including Stone Ridge Asset Management, Raymond James, Deutsche Bank and Wells Fargo. But why?

"While some may consider GW Pharma and Insys within the same peer group of investible stocks in the cannabis space, we think GW Pharma is in a class of its own, with the first FDA approval of a non-synthetic CBD based drug (Epidiolex) to hit the market," said Matt Karnes, Founder of GreenWave Advisors, a firm that analyzes cannabis companies. Karnes agreed that the two companies are frequently considered to be similar by people outside of the cannabis industry.

Insys is scheduled to report its second-quarter earnings on August 8 after the market closes. Three analysts give the company an average estimate of a -$0.16 per share for earnings. The average revenue estimate from five analysts is at $25.9 million. The average price target is $9.20. The growth estimates are -633%. And 14% of outstanding shares have been shorted, or 37% of the float.

Lazy investors will continue to lump Insys Therapeutics in the same category as GW Pharmaceuticals, even though the companies' drugs are very different. Patients deserve the best possible medical marijuana -- and if they can get it from the real plant, why buy a synthetic version? Investors also deserve the best possible biotech investment, so why settle for a fake one?

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no positions in any securities mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Cannabis | Markets | Stocks

More from Healthcare

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • 08:02 AM EST GARY BERMAN

    Tuesday Morning Fibocall for for 1/19/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login